A new artificial intelligence (AI) test can identify which men with prostate cancer will benefit most from the life-extending drug abiraterone, in clinical trial results presented by scientists from UCL and the Institute of Cancer Research.
The researchers analyzed prostate cancer tumour samples from men with high-risk prostate cancer that had not spread, who took part in the STAMPEDE trial. Using the new AI test, they found that abiraterone given alongside standard hormone therapy almost halves the risk of death for approximately 25% of men with this type of cancer.
However, since many men do well with standard therapy, there is a need to better select those who would gain the most benefit.
Experts say that because fewer men than previously thought will need the drug, NHS England should review…